Literature DB >> 752065

The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification.

C J Davis, W G Bradley, R Madrid.   

Abstract

1. A clinical, genetic, electrophysiological and nerve biopsy study of 49 index cases with peroneal muscular atrophy is reported. 2. In dominantly inherited cases, motor conduction velocities of the upper limbs within kinships indicated segregation into five groups which we have termed: a) hypertrophic neuropathy (less than 25 m/sec); b) intermediate group (25-45 m/sec); c) neuronal sensorimotor neuropathy (greater than 45 m/sec); d) neuronal motor neuropathy (greater than 45 m/sec); e) neuronal motor neuropathy with upper motor neurone involvement (greater than 45 m/sec). 3. The intermediate group is distinguished from the hypertrophic neuropathy group by the absence of clinically observed nerve hypertrophy and by the presence of a number of clinical features, including a more rapidly progressive disease. It is concluded to be genetically separate. This group is similarly quite distinct from the neuronal groups. Nerve biopsy studies support this view (Madrid et al., 1977; Bradley et al., 1977). 4. There was a relationship between severity of the disease and the conduction velocity which was most evident in the intermediate group. 5. There appeared to be an increase in motor conduction velocity with age in the hypertrophic neuropathy group, while the velocity fell in older patients in the intermediate group. 6. Sensory conduction velocity generally paralleled motor velocity but showed relatively less reduction. 7. Upper motor neurone features were not uncommon, appearing particularly in the intermediate group. Their presence may not therefore be a reliable basis for the classification of cases of peroneal muscular atrophy. 8. Tremor was observed in the hypertrophic, intermediate and neuronal motor neuropathy groups of patients, and does not provide a useful criterion for the classification of peroneal muscular atrophy. 9. There was occasional evidence to suggest poor or abnormal expression of the gene in dominantly inherited cases. Until more specific markers are available sporadic cases should be classified on the basis of the dominant forms, though they show a greater variability.

Entities:  

Mesh:

Year:  1978        PMID: 752065

Source DB:  PubMed          Journal:  J Genet Hum        ISSN: 0021-7743


  40 in total

1.  NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype.

Authors:  José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

2.  Comparison of CMT1A and CMT2: similarities and differences.

Authors:  Henriette M E Bienfait; Camiel Verhamme; Ivo N van Schaik; Johannes H T M Koelman; Bram W Ongerboer de Visser; Rob J de Haan; Frank Baas; Baziel G M van Engelen; Marianne de Visser
Journal:  J Neurol       Date:  2006-08-28       Impact factor: 4.849

3.  Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease.

Authors:  Bing-Wen Soong; Yen-Hua Huang; Pei-Chien Tsai; Chien-Chang Huang; Hung-Chuan Pan; Yi-Chun Lu; Hsin-Ju Chien; Tze-Tze Liu; Ming-Hong Chang; Kon-Ping Lin; Pang-Hsien Tu; Lung-Sen Kao; Yi-Chung Lee
Journal:  Am J Hum Genet       Date:  2013-02-21       Impact factor: 11.025

4.  Genetic linkage studies in hereditary motor and sensory neuropathies.

Authors:  F Leblhuber; F Reisecker; W R Mayr
Journal:  J Neurol       Date:  1986-10       Impact factor: 4.849

5.  Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy.

Authors:  Derek Atkinson; Jelena Nikodinovic Glumac; Bob Asselbergh; Biljana Ermanoska; David Blocquel; Regula Steiner; Alejandro Estrada-Cuzcano; Kristien Peeters; Tinne Ooms; Els De Vriendt; Xiang-Lei Yang; Thorsten Hornemann; Vedrana Milic Rasic; Albena Jordanova
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

Review 6.  Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease.

Authors:  D Pareyson; V Scaioli; M Laurà
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 7.  Intermediate forms of Charcot-Marie-Tooth neuropathy: a review.

Authors:  Garth Nicholson; Simon Myers
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 8.  Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Authors:  José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

9.  Genotype-phenotype correlation and frequency of distribution in a cohort of Chinese Charcot-Marie-Tooth patients associated with GDAP1 mutations.

Authors:  Pukar Singh Pakhrin; Yongzhi Xie; Zhengmao Hu; Xiaobo Li; Lei Liu; Shunxiang Huang; Binghao Wang; Zihan Yang; Jiejun Zhang; Xin Liu; Kun Xia; Beisha Tang; Ruxu Zhang
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

10.  Autosomal recessive hereditary motor and sensory neuropathy with mental retardation, optic atrophy and pyramidal signs.

Authors:  K D MacDermot; R W Walker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.